Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rak trzustki, który nie można operacyjnie usunąć lub który dał przerzuty
- •Widoczne zmiany w badaniach tomograficznych lub rezonansowych
- •Próbka guza dostępna do badań genetycznych
- •Ogólny stan zdrowia pozwalający na podjęcie leczenia (wskaźnik ECOG 0-1)
- •Spodziewana długość życia ponad 3 miesiące
- •Prawidłowe wyniki krwi: wystarczająca liczba białych i czerwonych krwinek oraz płytek
- •Prawidłowa funkcja wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (28)
Centro Di Riferimento Oncologico Di Aviano
Aviano, Italy
University Hospital Consorziale Policlinico
Bari, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, Italy
ASST Ospedale Maggiore di Crema
Crema, Italy
Azienda Socio Sanitaria Territoriale Di Cremona
Cremona, Italy
Careggi University Hospital
Florence, Italy
IRCCS Ospedale Policlinico San Martino
Genoa, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Meldola, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto Europeo Di Oncologia S.r.l.
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Humanitas Istituto Clinico Catanese S.p.A.
Misterbianco, Italy
Azienda Sanitaria Locale Napoli 1 Centro
Naples, Italy
Azienda Ospedaliero-Universitaria Maggiore Della Carità
Novara, Italy
Istituto Oncologico Veneto
Padova, Italy
Azienda Ospedaliero Universitaria Parma
Parma, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Azienda Sanitaria Territoriale Di Pesaro E Urbino
Pesaro, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Azienda Sanitaria Locale Della Provincia Di Biella
Ponderano, Italy
Azienda USL Toscana Centro
Prato, Italy
Azienda Unita Sanitaria Locale Della Romagna
Ravenna, Italy
I.F.O. Istituti Fisioterapici Ospitalieri
Rome, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Humanitas Mirasole S.p.A.
Rozzano, Italy
Pia Fondazione Di Culto E Religione Cardinale Giovanni Panico
Tricase, Italy
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Italy
Trial contact
Monica Niger, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.